Isomorphic Labs
Alphabet's AI drug-discovery company, spun out of Google DeepMind and led by Demis Hassabis; raised a $5B Series C in November 2026 to take drug candidates into clinical trials.
Isomorphic Labs is the Alphabet company that applies Google DeepMind’s structure-prediction work to drug discovery. Demis Hassabis runs it alongside DeepMind, and it has partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Funding
On Nov 17 2026 it raised a $5B Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and existing investors including GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. It did not disclose a valuation; Bloomberg had reported talks at about $50B (as relayed by TechCrunch). The round, which follows a $2.1B Series B in May 2026, is meant to take its drug candidates into clinical trials.
Timeline
Every dated event in the wiki that involves Isomorphic Labs, newest first.
- Isomorphic Labs raises a $5B Series C to take drug candidates into clinical trials
Greenoaks and Sequoia Capital co-led; Andreessen Horowitz is new, and existing backers include GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The valuation was not disclosed; Bloomberg had reported talks at about $50B. It follows a $2.1B Series B in May. The Google DeepMind spinout has drug-discovery partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Connections
Isomorphic Labs and everything one link away. Drag to move, scroll to zoom, click a node to open it.Open in the full graph →